Verification evidence is still being completed.
PDF / print export
Synthaverse S.A.
Lublin, Poland
- Verified lead
- Mieczyslaw Starkowicz
- Lead status
- STATUS: VERIFIED APRIL 2026
- Leadership verification
- President of the Management Board and Chief Executive Officer
- 2026 technical specialization
- Vaccine and Immunological Biotherapeutics Manufacturing, Onko BCG, and Distreptaza
- Review cycle
- 24 April 2026
- Full address
- ul. Uniwersytecka 10, 20-029 Lublin, Poland
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Invest in Lublin interview naming Mieczyslaw Starkowicz as President of the Management Board of Synthaverse.
- Editorial note
- Lublin vaccine and immunological biotherapeutics manufacturer with named president, GMP production, WSE listing BML, and Onko BCG immunotherapy for bladder cancer.
Vaccine and Immunological Biotherapeutics Manufacturing, Onko BCG, and Distreptaza
GMP vaccine manufacturing, WSE BML listing, Public president disclosure
Lublin vaccine and immunological biotherapeutics manufacturer with named president, GMP production, WSE listing BML, and Onko BCG immunotherapy for bladder cancer.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
Company profile · Lublin, Poland
Synthaverse S.A.
Vaccine and Immunological Biotherapeutics Manufacturing, Onko BCG, and Distreptaza · GMP vaccine manufacturing
Lublin vaccine and immunological biotherapeutics manufacturer with named president, GMP production, WSE listing BML, and Onko BCG immunotherapy for bladder cancer.
- Lead
- Mieczyslaw Starkowicz (verified ↗)
- Address
- ul. Uniwersytecka 10, 20-029 Lublin, Poland (source ↗)
- Compliance
- GMP vaccine manufacturing
- Last reviewed
- 24 Apr 2026 (1mo ago)
- Scale
- GMP vaccine manufacturing
- Capabilities
- BCG Vaccine Manufacturing · Onko BCG for Bladder Cancer · Laboratory Reagents and OTC Pharmaceuticals
- Founded
- 1944
- Headcount
- 201-500
- Company page (open ↗)
Clinical profileSTATUS: VERIFIED APRIL 2026
Mieczyslaw Starkowicz
President of the Management Board and Chief Executive Officer
Full addressul. Uniwersytecka 10, 20-029 Lublin, Poland
Site coordinatesVerification evidence is still being completed.
Review cycle24 April 2026
GMP vaccine manufacturing
Lublin, Poland. Vaccine and Immunological Biotherapeutics Manufacturing, Onko BCG, and Distreptaza. Review completed on 24 Apr 2026.
Polish Office for Registration of Medicinal Products and EMA for vaccine oversight
GMP vaccine manufacturing, WSE BML listing, Public president disclosure
Vaccine and Immunological Biotherapeutics Manufacturing, Onko BCG, and Distreptaza
Lublin vaccine and immunological biotherapeutics manufacturer with named president, GMP production, WSE listing BML, and Onko BCG immunotherapy for bladder cancer.
Editorial note
Synthaverse is a Lublin vaccine manufacturer with a named president, GMP vaccine production, Warsaw Stock Exchange listing BML, and the Onko BCG immunotherapy product for bladder cancer.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleApril 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
BCG Vaccine Manufacturing
Onko BCG for Bladder Cancer
Laboratory Reagents and OTC Pharmaceuticals
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
Vaccine production suites
Immunotherapy manufacturing
OTC and Rx pharmaceutical lines
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- VERIFIED ACTIVE 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
24 Apr 2026: Executive identity confirmed via official management disclosure.
24 Apr 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is Synthaverse S.A. located?
- Synthaverse S.A. operates from ul. Uniwersytecka 10, 20-029 Lublin, Poland, Lublin, Poland.
- Who runs Synthaverse S.A.?
- Synthaverse S.A. is led by Mieczyslaw Starkowicz, President of the Management Board and Chief Executive Officer. Verified 24 Apr 2026.
- What certifications does Synthaverse S.A. hold?
- Synthaverse S.A. is documented under GMP vaccine manufacturing.
- What does Synthaverse S.A. do?
- Lublin vaccine and immunological biotherapeutics manufacturer with named president, GMP production, WSE listing BML, and Onko BCG immunotherapy for bladder cancer. Core capabilities: BCG Vaccine Manufacturing, Onko BCG for Bladder Cancer, Laboratory Reagents and OTC Pharmaceuticals.
Editorial context
Related technical briefs
Briefs that name Lublin as a covered market or city.